<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02669017</url>
  </required_header>
  <id_info>
    <org_study_id>ADCT-402-101</org_study_id>
    <secondary_id>2016-000952-92</secondary_id>
    <nct_id>NCT02669017</nct_id>
  </id_info>
  <brief_title>Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)</brief_title>
  <official_title>A Phase 1 Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ADC Therapeutics S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ADC Therapeutics S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates ADCT-402 in participants with Relapsed or Refractory B-cell Lineage Non
      Hodgkin Lymphoma (B-NHL). Participants will participate in a dose escalation phase (Part 1)
      and dose expansion (Part 2). In Part 2, participants will receive the dose level identified
      in Part 1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study ADCT-402-101 is the first clinical study with ADCT-402 in participants with B-cell Non
      Hodgkin Lymphoma (NHL).

      ADCT-402 is an antibody drug conjugate (ADC) composed of a humanized antibody directed
      against human cluster of differentiation 19 (CD19), stochastically conjugated via a
      valine-alanine cleavable, maleimide linker to a pyrrolobenzodiazepine (PBD) dimer cytotoxin.

      The study will be conducted in 2 parts. In Part 1 (dose escalation) participants will receive
      infusions of ADCT-402, at escalating doses. Part 1 will continue until the maximum tolerated
      dose is determined. In Part 2 (expansion), participants will be assigned to the recommended
      dose level(s) and schedule(s) of ADCT-402 identified in Part 1 by the Dose Escalation
      Steering Committee.

      For each participant, the study will include a screening period (up to 28 days), a treatment
      period (until withdrawal), and a follow-up period to assess disease progression and survival
      for up to 12 months after the last dose of study drug. The total study duration will be
      dependent on overall participant tolerability to the study drug and response to treatment. It
      is anticipated that the duration of the entire study (Parts 1 and 2) could be approximately 3
      years from first participant treated to last participant completed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">February 21, 2019</completion_date>
  <primary_completion_date type="Actual">February 21, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>Q3W schedule: Day 1 to End of Cycle 1 (3 weeks); Q6W schedule: Day 1 to End of Cycle 1 (6 weeks)</time_frame>
    <description>A DLT is defined as any of the following events, except those that are clearly due to underlying disease or extraneous causes:
A hematologic DLT is defined as:
CTCAE Grade 3 or 4 febrile neutropenia or neutropenic infection.
CTCAE Grade 4 neutropenia lasting &gt;7 days.
CTCAE Grade 4 thrombocytopenia.
CTCAE Grade 3 thrombocytopenia with clinically significant bleeding, or Grade 3 thrombocytopenia requiring a platelet transfusion.
CTCAE Grade 4 anemia.
A non-hematologic DLT is defined as:
CTCAE Grade 4 tumor lysis syndrome (TLS). Grade 3 TLS will not constitute DLT unless it leads to irreversible end-organ damage.
CTCAE Grade 3 or higher AE (including nausea, vomiting, diarrhea, and electrolyte imbalances lasting more than 48 hours despite optimal therapy; excluding all grades of alopecia).
CTCAE Grade 3 or higher hypersensitivity reaction (regardless of premedication).
CTCAE Grade 2 or higher skin ulceration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Dose of ADCT-402 for Part 2</measure>
    <time_frame>Q3W schedule: Day 1 to End of Cycle 1 (3 weeks); Q6W schedule: Day 1 to End of Cycle 1 (6 weeks)</time_frame>
    <description>The recommended dose was established by the dose escalation steering committee and based on safety findings during Part 1 of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting at Least One Treatment Emergent Adverse Event (TEAE)</measure>
    <time_frame>Day 1 to End of Study (a maximum of 18 months)</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a participants enrolled into this study regardless of its causal relationship to study drug. A TEAE is defined as any event not present before exposure to study drug or any event already present that worsens in either intensity or frequency after exposure to study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting at Least One Treatment Emergent Serious Adverse Event (SAE)</measure>
    <time_frame>Day 1 to End of Study (a maximum of 18 months)</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant enrolled into this study regardless of its causal relationship to study drug. A treatment emergent AE (TEAE) is defined as any event not present before exposure to study drug or any event already present that worsens in either intensity or frequency after exposure to study drug. An SAE is defined as any event that results in death, is immediately life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Baseline to End of Study (a maximum of 18 months)</time_frame>
    <description>ORR was defined as the number of participants with a best overall response of complete response (CR) or partial response (PR) at the time each participant discontinued treatment with ADCT-402, before the start of subsequent anticancer therapy or procedure. Tumor response was assessed using the 2014 Lugano Classification for response.
CR is defined as achieving either of the following:
Complete metabolic response.
Complete radiologic response (target node regress to &lt;1.5 cm, no nonmeasured lesions, no organ enlargement, no new lesions and normal bone marrow morphology).
PR is defined as achieving either of the following:
Partial metabolic response (findings indicate residual disease).
Partial remission (&gt;50% decrease in target measurable nodes, regression/ absence/ no increase of nonmeasured lesions, spleen regressed by &gt;50% in length and no new lesions).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Baseline to End of Study (a maximum of 18 months)</time_frame>
    <description>DoR is defined among responders (complete response [CR] and partial response [PR]) as the time from the earliest date of first response until the first date of either disease progression or death due to any cause. Tumor response was assessed using the 2014 Lugano Classification for response.
Disease progression is defined as progressive metabolic disease or one of the follow:
Target node progression.
An individual extranodal lesion must be abnormal with length &gt;1.5cm and/or increase of length &gt;50%.
New or clear progression of nonmeasured lesions.
Regrowth of previously resolved lesions or new nodes &gt;1.5 cm in length.
New or recurrent bone marrow involvement.
DoR is presented overall for all participants who received ADCT-402, as specified in protocol section 7.4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline to End of Study (a maximum of 18 months)</time_frame>
    <description>OS is defined as the time from the first dose of study drug treatment until the date of death due to any cause.
OS is presented overall for all participants who received ADCT-402, as specified in protocol section 7.4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Baseline to End of Study (a maximum of 18 months)</time_frame>
    <description>PFS is defined among the efficacy population as the time from first dose of study drug until either disease progression or death due to any cause. Tumor response was assessed using the 2014 Lugano Classification for response.
Disease progression is defined as progressive metabolic disease or one of the follow:
Target node progression.
An individual extranodal lesion must be abnormal with length &gt;1.5cm and/or increase of length &gt;50%.
New or clear progression of nonmeasured lesions.
Regrowth of previously resolved lesions or new nodes &gt;1.5 cm in length.
New or recurrent bone marrow involvement.
PFS is presented overall for all participants who received ADCT-402, as specified in protocol section 7.4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) for ADCT-402</measure>
    <time_frame>Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)</time_frame>
    <description>Cmax for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach the Maximum Serum Concentration (Tmax) for ADCT-402</measure>
    <time_frame>Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)</time_frame>
    <description>Tmax for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) for ADCT-402</measure>
    <time_frame>Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)</time_frame>
    <description>AUClast for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-Time Curve From Time 0 to the End of the Dosing Interval (AUCtau) for ADCT-402</measure>
    <time_frame>Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)</time_frame>
    <description>AUCtau for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf) for ADCT-402</measure>
    <time_frame>Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)</time_frame>
    <description>AUCinf for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life (Thalf) of ADCT-402</measure>
    <time_frame>Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)</time_frame>
    <description>Thalf of Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL) at Steady State for ADCT-402</measure>
    <time_frame>Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)</time_frame>
    <description>CL of Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) for ADCT-402</measure>
    <time_frame>Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)</time_frame>
    <description>Vss for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Index (AI) for ADCT-402</measure>
    <time_frame>Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)</time_frame>
    <description>AI for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199). AI is the ratio of area under the serum concentration-time curve (AUC) from 0 to 21 days for Cycle 2 divided by AUC from 0 to 21 days for Cycle 1 (Q3W schedule: 3 week cycle length; Q6W schedule: 6 week cycle length). It is the increase in drug plasma concentration after multiple dosing until a steady state is reached.
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-drug Antibody Response (ADA) Against ADCT-402</measure>
    <time_frame>Q3W schedule: Day 1 to End of Cycle 1 (3 weeks); Q6W schedule: Day 1 to End of Cycle 1 (6 weeks)</time_frame>
    <description>Blood serum samples were collected and analysed to determine the presence or absence of ADA.
ADA is presented overall for all participants who received ADCT-402, as specified in protocol section 7.4.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">183</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Burkitt's Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <condition>Lymphoma, Follicular</condition>
  <condition>Lymphoma, Mantle-Cell</condition>
  <condition>Lymphoma, Marginal Zone</condition>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <condition>Primary Mediastinal B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Part 1: ADCT-402 dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1 (dose escalation) participants will receive intravenous (IV) infusions of ADCT-402 at escalating doses, according to a 3+3 study design. Doses will be escalated from 15 µg/kg to 200 µg/kg on Day 1 of each cycle, with cycle lengths of 3 or 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: ADCT-402 dose expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 2 (expansion), participants will be assigned to the recommended dose level(s) and schedule(s) of ADCT-402 identified in Part 1 by the Dose Escalation Steering Committee.
Participants will receive intravenous (IV) infusions of ADCT-402 at either 120 μg/kg or 150 μg/kg on Day 1 of each 3 week cycle (Q3W).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADCT-402</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>Part 1: ADCT-402 dose escalation</arm_group_label>
    <arm_group_label>Part 2: ADCT-402 dose expansion</arm_group_label>
    <other_name>Loncastuximab tesirine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female participants, ages 18 years or older with pathologically confirmed
             relapsed or refractory B-cell lineage NHL who have failed or are intolerant to
             established therapy, or for whom no other treatment options are available.

          -  Refractory or relapsed B-cell NHL (per World health Organization [WHO] Classification
             system).

          -  Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block.

          -  Measurable disease, as defined by the 2014 Lugano Classification.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

          -  Absolute neutrophil count (ANC) ≥1000/μL.

          -  Platelet count of ≥75000/μL.

          -  Hemoglobin ≥9.0 g/dL without transfusion within the 2 weeks prior to Day 1.

          -  Serum/plasma creatinine ≤1.5 mg/dL.

          -  Serum/plasma alkaline phosphatase, alanine aminotransferase (ALT), and aspartate
             aminotransferase (AST) ≤2 times the upper limit of normal (ULN); ≤ 5 times ULN if
             there is liver or bone involvement.

          -  Total serum/plasma bilirubin ≤1.5 times ULN.

          -  Negative blood or urine beta-human chorionic gonadotropin (β-HCG) pregnancy test
             within 7 days prior to Day 1 for women of childbearing potential.

          -  Males, and female participants who are biologically capable of having children, must
             agree to use a medically acceptable method of birth control.

        Exclusion Criteria:

          -  Participants who have any option for other treatment for B-cell NHL at the current
             state of disease.

          -  Active graft-versus-host disease.

          -  Autologous or allogenic transplant within the 60 days prior to the Screening visit.

          -  Known history of immunogenicity or hypersensitivity to a CD19 antibody.

          -  Evidence of myelodysplasia or myeloid leukemia by morphology, immunostains, flow
             cytometry, or cytogenetics on a bone marrow aspirate or biopsy.

          -  Known history of positive serum human ADA.

          -  Active autoimmune disease, motor neuropathy considered of autoimmune origin, and other
             central nervous system (CNS) autoimmune disease.

          -  Known seropositive for human immunodeficiency (HIV) virus, hepatitis B surface antigen
             (HbsAg), or antibody to hepatitis C virus (anti-HCV).

          -  History of Steven's Johnson's syndrome or toxic epidermal necrolysis syndrome.

          -  Pregnant or breastfeeding women.

          -  Significant medical comorbidities, including uncontrolled hypertension (diastolic
             blood pressure greater than 115 mm Hg), unstable angina, congestive heart failure
             (greater than New York Heart Association class II), severe uncontrolled ventricular
             arrhythmias, or electrocardiographic evidence of acute ischemia, poorly controlled
             diabetes, severe chronic pulmonary disease, coronary angioplasty, or myocardial
             infarction within 6 months prior to screening, or uncontrolled atrial or ventricular
             cardiac arrhythmias.

          -  Use of any other experimental medication(s) within 14 days or 5 half-lives but in no
             case less than 14 days prior to start of study treatment on Cycle 1, Day 1, except if
             approved by Sponsor.

          -  Steroid use equivalent to greater than 20 mg of prednisone within 4 weeks (28 days)
             prior to Day 1.

          -  Major surgery, chemotherapy, systemic therapy (excluding steroids hydroxyurea
             steroids, and any targeted small molecules or biologics), or radiotherapy, within 14
             days or 5 half-lives (whichever is shorter) prior to Cycle 1, Day 1 treatment, except
             if approved by the Sponsor.

          -  Failure to recover (to Common Terminology Criteria for Adverse Events [CTCAE] Grade 0
             or Grade 1) from acute non hematologic toxicity (except all grades alopecia or Grade 2
             or lower neuropathy), due to previous therapy, prior to Screening.

          -  Congenital long QT syndrome or a corrected QTc interval ≥450 ms at the Screening
             visit.

          -  Active second primary malignancy other than non-melanoma skin cancers, non-metastatic
             prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the
             breast, or other malignancy determined not be exclusionary.

          -  Any other significant medical illness, abnormality, or condition that would make the
             participant inappropriate for study participation or put the participant at risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blood and Marrow Transplant Group of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center Herbert Irving Pavilion</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Health System, Institute for Translational Oncology Research, Clinical Research Unit</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital &amp; the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O Oncologia e Ematologia - Istituto Clinico Humanitas</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 21, 2016</study_first_submitted>
  <study_first_submitted_qc>January 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2016</study_first_posted>
  <results_first_submitted>February 19, 2020</results_first_submitted>
  <results_first_submitted_qc>March 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2020</results_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Loncastuximab tesirine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02669017/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02669017/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were screened at 11 sites in 3 countries.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1: 15 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="P2">
          <title>Part 1: 30 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="P3">
          <title>Part 1: 60 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="P4">
          <title>Part 1: 90 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="P5">
          <title>Part 1: 120 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="P6">
          <title>Part 2: 120 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="P7">
          <title>Part 1: 150 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="P8">
          <title>Part 2: 150 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="P9">
          <title>Part 1: 200 μg/kg Q3W and Q6W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Following protocol amendment 5, treatment cycle length was increased to 6 weeks (Q6W).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="26"/>
                <participants group_id="P7" count="19"/>
                <participants group_id="P8" count="69"/>
                <participants group_id="P9" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="11"/>
                <participants group_id="P8" count="62"/>
                <participants group_id="P9" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="47"/>
                <participants group_id="P9" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="13"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who received at least one dose of study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Part 1: 15 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="B2">
          <title>Part 1: 30 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="B3">
          <title>Part 1: 60 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="B4">
          <title>Part 1: 90 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="B5">
          <title>Part 1: 120 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="B6">
          <title>Part 2: 120 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="B7">
          <title>Part 1: 150 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="B8">
          <title>Part 2: 150 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="B9">
          <title>Part 1: 200 μg/kg Q3W and Q6W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Following protocol amendment 5, treatment cycle length was increased to 6 weeks (Q6W).</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="16"/>
            <count group_id="B6" value="26"/>
            <count group_id="B7" value="19"/>
            <count group_id="B8" value="69"/>
            <count group_id="B9" value="36"/>
            <count group_id="B10" value="183"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="4"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="16"/>
                    <count group_id="B6" value="26"/>
                    <count group_id="B7" value="19"/>
                    <count group_id="B8" value="69"/>
                    <count group_id="B9" value="36"/>
                    <count group_id="B10" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="13"/>
                    <measurement group_id="B8" value="43"/>
                    <measurement group_id="B9" value="19"/>
                    <measurement group_id="B10" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="26"/>
                    <measurement group_id="B9" value="17"/>
                    <measurement group_id="B10" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="4"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="16"/>
                    <count group_id="B6" value="26"/>
                    <count group_id="B7" value="19"/>
                    <count group_id="B8" value="69"/>
                    <count group_id="B9" value="36"/>
                    <count group_id="B10" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.5" spread="8.39"/>
                    <measurement group_id="B2" value="68.3" spread="11.53"/>
                    <measurement group_id="B3" value="51.3" spread="18.82"/>
                    <measurement group_id="B4" value="68.2" spread="12.38"/>
                    <measurement group_id="B5" value="71.0" spread="10.20"/>
                    <measurement group_id="B6" value="63.7" spread="13.37"/>
                    <measurement group_id="B7" value="58.5" spread="13.96"/>
                    <measurement group_id="B8" value="58.7" spread="15.82"/>
                    <measurement group_id="B9" value="61.7" spread="12.82"/>
                    <measurement group_id="B10" value="61.7" spread="14.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="4"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="16"/>
                    <count group_id="B6" value="26"/>
                    <count group_id="B7" value="19"/>
                    <count group_id="B8" value="69"/>
                    <count group_id="B9" value="36"/>
                    <count group_id="B10" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="34"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="13"/>
                    <measurement group_id="B8" value="35"/>
                    <measurement group_id="B9" value="26"/>
                    <measurement group_id="B10" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="4"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="16"/>
                    <count group_id="B6" value="26"/>
                    <count group_id="B7" value="19"/>
                    <count group_id="B8" value="69"/>
                    <count group_id="B9" value="36"/>
                    <count group_id="B10" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="25"/>
                    <measurement group_id="B7" value="18"/>
                    <measurement group_id="B8" value="65"/>
                    <measurement group_id="B9" value="35"/>
                    <measurement group_id="B10" value="176"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="4"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="16"/>
                    <count group_id="B6" value="26"/>
                    <count group_id="B7" value="19"/>
                    <count group_id="B8" value="69"/>
                    <count group_id="B9" value="36"/>
                    <count group_id="B10" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="19"/>
                    <measurement group_id="B8" value="61"/>
                    <measurement group_id="B9" value="35"/>
                    <measurement group_id="B10" value="164"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaskan Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <population>Height data was not collected for 2 participants because of complications during the collection of baseline measurements.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="4"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="16"/>
                    <count group_id="B6" value="26"/>
                    <count group_id="B7" value="19"/>
                    <count group_id="B8" value="68"/>
                    <count group_id="B9" value="35"/>
                    <count group_id="B10" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172.23" spread="18.438"/>
                    <measurement group_id="B2" value="170.73" spread="12.545"/>
                    <measurement group_id="B3" value="173.65" spread="11.544"/>
                    <measurement group_id="B4" value="167.68" spread="10.275"/>
                    <measurement group_id="B5" value="170.72" spread="8.977"/>
                    <measurement group_id="B6" value="171.47" spread="9.790"/>
                    <measurement group_id="B7" value="172.79" spread="10.584"/>
                    <measurement group_id="B8" value="170.56" spread="11.908"/>
                    <measurement group_id="B9" value="171.29" spread="12.193"/>
                    <measurement group_id="B10" value="171.11" spread="11.221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="4"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="16"/>
                    <count group_id="B6" value="26"/>
                    <count group_id="B7" value="19"/>
                    <count group_id="B8" value="69"/>
                    <count group_id="B9" value="36"/>
                    <count group_id="B10" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.65" spread="7.204"/>
                    <measurement group_id="B2" value="78.73" spread="25.445"/>
                    <measurement group_id="B3" value="79.95" spread="26.942"/>
                    <measurement group_id="B4" value="86.38" spread="23.597"/>
                    <measurement group_id="B5" value="86.89" spread="25.996"/>
                    <measurement group_id="B6" value="78.66" spread="18.113"/>
                    <measurement group_id="B7" value="88.67" spread="20.820"/>
                    <measurement group_id="B8" value="77.87" spread="22.453"/>
                    <measurement group_id="B9" value="88.71" spread="24.834"/>
                    <measurement group_id="B10" value="82.23" spread="22.635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <population>BMI could not be calculated for 2 participants due to missing height information.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="4"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="16"/>
                    <count group_id="B6" value="26"/>
                    <count group_id="B7" value="19"/>
                    <count group_id="B8" value="68"/>
                    <count group_id="B9" value="35"/>
                    <count group_id="B10" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.21" spread="3.971"/>
                    <measurement group_id="B2" value="26.60" spread="5.466"/>
                    <measurement group_id="B3" value="25.89" spread="5.428"/>
                    <measurement group_id="B4" value="30.77" spread="8.931"/>
                    <measurement group_id="B5" value="29.40" spread="6.882"/>
                    <measurement group_id="B6" value="26.68" spread="5.458"/>
                    <measurement group_id="B7" value="29.57" spread="5.575"/>
                    <measurement group_id="B8" value="26.62" spread="6.648"/>
                    <measurement group_id="B9" value="30.15" spread="7.235"/>
                    <measurement group_id="B10" value="27.93" spread="6.587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="4"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="16"/>
                    <count group_id="B6" value="26"/>
                    <count group_id="B7" value="19"/>
                    <count group_id="B8" value="69"/>
                    <count group_id="B9" value="36"/>
                    <count group_id="B10" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0: Fully Active</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="20"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1: Restricted in Physical Activity; Ambulatory</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="36"/>
                    <measurement group_id="B9" value="21"/>
                    <measurement group_id="B10" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2: Ambulatory and Capable of All Self-care</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3: Capable of Only Limited Self-care</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4: Completely Disabled</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5: Dead</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)</title>
        <description>A DLT is defined as any of the following events, except those that are clearly due to underlying disease or extraneous causes:
A hematologic DLT is defined as:
CTCAE Grade 3 or 4 febrile neutropenia or neutropenic infection.
CTCAE Grade 4 neutropenia lasting &gt;7 days.
CTCAE Grade 4 thrombocytopenia.
CTCAE Grade 3 thrombocytopenia with clinically significant bleeding, or Grade 3 thrombocytopenia requiring a platelet transfusion.
CTCAE Grade 4 anemia.
A non-hematologic DLT is defined as:
CTCAE Grade 4 tumor lysis syndrome (TLS). Grade 3 TLS will not constitute DLT unless it leads to irreversible end-organ damage.
CTCAE Grade 3 or higher AE (including nausea, vomiting, diarrhea, and electrolyte imbalances lasting more than 48 hours despite optimal therapy; excluding all grades of alopecia).
CTCAE Grade 3 or higher hypersensitivity reaction (regardless of premedication).
CTCAE Grade 2 or higher skin ulceration.</description>
        <time_frame>Q3W schedule: Day 1 to End of Cycle 1 (3 weeks); Q6W schedule: Day 1 to End of Cycle 1 (6 weeks)</time_frame>
        <population>All participants in Part 1 who completed at least one cycle of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 15 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 60 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 90 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 120 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 150 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 200 μg/kg Q3W and Q6W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Following protocol amendment 5, treatment cycle length was increased to 6 weeks (Q6W).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)</title>
          <description>A DLT is defined as any of the following events, except those that are clearly due to underlying disease or extraneous causes:
A hematologic DLT is defined as:
CTCAE Grade 3 or 4 febrile neutropenia or neutropenic infection.
CTCAE Grade 4 neutropenia lasting &gt;7 days.
CTCAE Grade 4 thrombocytopenia.
CTCAE Grade 3 thrombocytopenia with clinically significant bleeding, or Grade 3 thrombocytopenia requiring a platelet transfusion.
CTCAE Grade 4 anemia.
A non-hematologic DLT is defined as:
CTCAE Grade 4 tumor lysis syndrome (TLS). Grade 3 TLS will not constitute DLT unless it leads to irreversible end-organ damage.
CTCAE Grade 3 or higher AE (including nausea, vomiting, diarrhea, and electrolyte imbalances lasting more than 48 hours despite optimal therapy; excluding all grades of alopecia).
CTCAE Grade 3 or higher hypersensitivity reaction (regardless of premedication).
CTCAE Grade 2 or higher skin ulceration.</description>
          <population>All participants in Part 1 who completed at least one cycle of treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="16"/>
                <count group_id="O7" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Recommended Dose of ADCT-402 for Part 2</title>
        <description>The recommended dose was established by the dose escalation steering committee and based on safety findings during Part 1 of the study.</description>
        <time_frame>Q3W schedule: Day 1 to End of Cycle 1 (3 weeks); Q6W schedule: Day 1 to End of Cycle 1 (6 weeks)</time_frame>
        <population>All participants in Part 1 who completed at least one cycle of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: ADCT-402 Dose Escalation</title>
            <description>In Part 1 (dose escalation) participants received intravenous (IV) infusions of ADCT-402, at escalating doses according to a 3+3 study design. Doses assessed:
Dose Level 1: 15 μg/kg on Day 1 of each 3 week cycle (Q3W)
Dose Level 2: 30 μg/kg Day 1 Q3W
Dose Level 3: 60 μg/kg Day 1 Q3W
Dose Level 4: 90 μg/kg Day 1 Q3W
Dose Level 5: 120 μg/kg Day 1 Q3W
Dose Level 6: 150 μg/kg Day 1 Q3W
Dose Level 7: 200 μg/kg Day 1 Q3W and on Day 1 of each 6 week cycle (Q6W).</description>
          </group>
        </group_list>
        <measure>
          <title>Recommended Dose of ADCT-402 for Part 2</title>
          <description>The recommended dose was established by the dose escalation steering committee and based on safety findings during Part 1 of the study.</description>
          <population>All participants in Part 1 who completed at least one cycle of treatment.</population>
          <units>μg/kg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Recommended Part 2 Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recommended Part 2 Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting at Least One Treatment Emergent Adverse Event (TEAE)</title>
        <description>An adverse event (AE) is defined as any untoward medical occurrence in a participants enrolled into this study regardless of its causal relationship to study drug. A TEAE is defined as any event not present before exposure to study drug or any event already present that worsens in either intensity or frequency after exposure to study drug.</description>
        <time_frame>Day 1 to End of Study (a maximum of 18 months)</time_frame>
        <population>All participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 15 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 60 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 90 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 120 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O6">
            <title>Part 2: 120 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 150 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O8">
            <title>Part 2: 150 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O9">
            <title>Part 1: 200 μg/kg Q3W and Q6W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Following protocol amendment 5, treatment cycle length was increased to 6 weeks (Q6W).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting at Least One Treatment Emergent Adverse Event (TEAE)</title>
          <description>An adverse event (AE) is defined as any untoward medical occurrence in a participants enrolled into this study regardless of its causal relationship to study drug. A TEAE is defined as any event not present before exposure to study drug or any event already present that worsens in either intensity or frequency after exposure to study drug.</description>
          <population>All participants who received at least one dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="19"/>
                <count group_id="O8" value="69"/>
                <count group_id="O9" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="26"/>
                    <measurement group_id="O7" value="19"/>
                    <measurement group_id="O8" value="68"/>
                    <measurement group_id="O9" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting at Least One Treatment Emergent Serious Adverse Event (SAE)</title>
        <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant enrolled into this study regardless of its causal relationship to study drug. A treatment emergent AE (TEAE) is defined as any event not present before exposure to study drug or any event already present that worsens in either intensity or frequency after exposure to study drug. An SAE is defined as any event that results in death, is immediately life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.</description>
        <time_frame>Day 1 to End of Study (a maximum of 18 months)</time_frame>
        <population>All participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 15 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 60 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 90 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 120 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O6">
            <title>Part 2: 120 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 150 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O8">
            <title>Part 2: 150 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O9">
            <title>Part 1: 200 μg/kg Q3W and Q6W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Following protocol amendment 5, treatment cycle length was increased to 6 weeks (Q6W).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting at Least One Treatment Emergent Serious Adverse Event (SAE)</title>
          <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant enrolled into this study regardless of its causal relationship to study drug. A treatment emergent AE (TEAE) is defined as any event not present before exposure to study drug or any event already present that worsens in either intensity or frequency after exposure to study drug. An SAE is defined as any event that results in death, is immediately life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.</description>
          <population>All participants who received at least one dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="19"/>
                <count group_id="O8" value="69"/>
                <count group_id="O9" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="14"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="40"/>
                    <measurement group_id="O9" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>ORR was defined as the number of participants with a best overall response of complete response (CR) or partial response (PR) at the time each participant discontinued treatment with ADCT-402, before the start of subsequent anticancer therapy or procedure. Tumor response was assessed using the 2014 Lugano Classification for response.
CR is defined as achieving either of the following:
Complete metabolic response.
Complete radiologic response (target node regress to &lt;1.5 cm, no nonmeasured lesions, no organ enlargement, no new lesions and normal bone marrow morphology).
PR is defined as achieving either of the following:
Partial metabolic response (findings indicate residual disease).
Partial remission (&gt;50% decrease in target measurable nodes, regression/ absence/ no increase of nonmeasured lesions, spleen regressed by &gt;50% in length and no new lesions).</description>
        <time_frame>Baseline to End of Study (a maximum of 18 months)</time_frame>
        <population>All participants who received at least one dose of study treatment with a valid baseline disease assessment and at least one valid post-baseline disease assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 15 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 60 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 90 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 120 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O6">
            <title>Part 2: 120 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 150 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O8">
            <title>Part 2: 150 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O9">
            <title>Part 1: 200 μg/kg Q3W and Q6W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Following protocol amendment 5, treatment cycle length was increased to 6 weeks (Q6W).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>ORR was defined as the number of participants with a best overall response of complete response (CR) or partial response (PR) at the time each participant discontinued treatment with ADCT-402, before the start of subsequent anticancer therapy or procedure. Tumor response was assessed using the 2014 Lugano Classification for response.
CR is defined as achieving either of the following:
Complete metabolic response.
Complete radiologic response (target node regress to &lt;1.5 cm, no nonmeasured lesions, no organ enlargement, no new lesions and normal bone marrow morphology).
PR is defined as achieving either of the following:
Partial metabolic response (findings indicate residual disease).
Partial remission (&gt;50% decrease in target measurable nodes, regression/ absence/ no increase of nonmeasured lesions, spleen regressed by &gt;50% in length and no new lesions).</description>
          <population>All participants who received at least one dose of study treatment with a valid baseline disease assessment and at least one valid post-baseline disease assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="19"/>
                <count group_id="O8" value="68"/>
                <count group_id="O9" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="25"/>
                    <measurement group_id="O9" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DoR)</title>
        <description>DoR is defined among responders (complete response [CR] and partial response [PR]) as the time from the earliest date of first response until the first date of either disease progression or death due to any cause. Tumor response was assessed using the 2014 Lugano Classification for response.
Disease progression is defined as progressive metabolic disease or one of the follow:
Target node progression.
An individual extranodal lesion must be abnormal with length &gt;1.5cm and/or increase of length &gt;50%.
New or clear progression of nonmeasured lesions.
Regrowth of previously resolved lesions or new nodes &gt;1.5 cm in length.
New or recurrent bone marrow involvement.
DoR is presented overall for all participants who received ADCT-402, as specified in protocol section 7.4.</description>
        <time_frame>Baseline to End of Study (a maximum of 18 months)</time_frame>
        <population>All participants who received at least one dose of study treatment with a valid baseline disease assessment and at least one valid post-baseline disease assessment. Results are pooled for all arms as specified in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Parts 1 and 2: ADCT-402</title>
            <description>In Part 1 (dose escalation) participants received intravenous (IV) infusions of ADCT-402, at escalating doses according to a 3+3 study design. Doses assessed:
Dose Level 1: 15 μg/kg on Day 1 of each 3 week cycle (Q3W)
Dose Level 2: 30 μg/kg Day 1 Q3W
Dose Level 3: 60 μg/kg Day 1 Q3W
Dose Level 4: 90 μg/kg Day 1 Q3W
Dose Level 5: 120 μg/kg Day 1 Q3W
Dose Level 6: 150 μg/kg Day 1 Q3W
Dose Level 7: 200 μg/kg Day 1 Q3W and on Day 1 of each 6 week cycle (Q6W).
In Part 2 (expansion), participants received intravenous (IV) infusions of ADCT-402 at either 120 μg/kg or 150 μg/kg on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DoR)</title>
          <description>DoR is defined among responders (complete response [CR] and partial response [PR]) as the time from the earliest date of first response until the first date of either disease progression or death due to any cause. Tumor response was assessed using the 2014 Lugano Classification for response.
Disease progression is defined as progressive metabolic disease or one of the follow:
Target node progression.
An individual extranodal lesion must be abnormal with length &gt;1.5cm and/or increase of length &gt;50%.
New or clear progression of nonmeasured lesions.
Regrowth of previously resolved lesions or new nodes &gt;1.5 cm in length.
New or recurrent bone marrow involvement.
DoR is presented overall for all participants who received ADCT-402, as specified in protocol section 7.4.</description>
          <population>All participants who received at least one dose of study treatment with a valid baseline disease assessment and at least one valid post-baseline disease assessment. Results are pooled for all arms as specified in the protocol.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.36" lower_limit="4.04" upper_limit="NA">Upper limit of the confidence interval was not reached.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS is defined as the time from the first dose of study drug treatment until the date of death due to any cause.
OS is presented overall for all participants who received ADCT-402, as specified in protocol section 7.4.</description>
        <time_frame>Baseline to End of Study (a maximum of 18 months)</time_frame>
        <population>All participants who received at least one dose of study treatment with a valid baseline disease assessment and at least one valid post-baseline disease assessment. Results are pooled for all arms as specified in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Parts 1 and 2: ADCT-402</title>
            <description>In Part 1 (dose escalation) participants received intravenous (IV) infusions of ADCT-402, at escalating doses according to a 3+3 study design. Doses assessed:
Dose Level 1: 15 μg/kg on Day 1 of each 3 week cycle (Q3W)
Dose Level 2: 30 μg/kg Day 1 Q3W
Dose Level 3: 60 μg/kg Day 1 Q3W
Dose Level 4: 90 μg/kg Day 1 Q3W
Dose Level 5: 120 μg/kg Day 1 Q3W
Dose Level 6: 150 μg/kg Day 1 Q3W
Dose Level 7: 200 μg/kg Day 1 Q3W and on Day 1 of each 6 week cycle (Q6W).
In Part 2 (expansion), participants received intravenous (IV) infusions of ADCT-402 at either 120 μg/kg or 150 μg/kg on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS is defined as the time from the first dose of study drug treatment until the date of death due to any cause.
OS is presented overall for all participants who received ADCT-402, as specified in protocol section 7.4.</description>
          <population>All participants who received at least one dose of study treatment with a valid baseline disease assessment and at least one valid post-baseline disease assessment. Results are pooled for all arms as specified in the protocol.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.25" lower_limit="6.74" upper_limit="10.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>PFS is defined among the efficacy population as the time from first dose of study drug until either disease progression or death due to any cause. Tumor response was assessed using the 2014 Lugano Classification for response.
Disease progression is defined as progressive metabolic disease or one of the follow:
Target node progression.
An individual extranodal lesion must be abnormal with length &gt;1.5cm and/or increase of length &gt;50%.
New or clear progression of nonmeasured lesions.
Regrowth of previously resolved lesions or new nodes &gt;1.5 cm in length.
New or recurrent bone marrow involvement.
PFS is presented overall for all participants who received ADCT-402, as specified in protocol section 7.4.</description>
        <time_frame>Baseline to End of Study (a maximum of 18 months)</time_frame>
        <population>All participants who received at least one dose of study treatment with a valid baseline disease assessment and at least one valid post-baseline disease assessment. Results are pooled for all arms as specified in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Parts 1 and 2: ADCT-402</title>
            <description>In Part 1 (dose escalation) participants received intravenous (IV) infusions of ADCT-402, at escalating doses according to a 3+3 study design. Doses assessed:
Dose Level 1: 15 μg/kg on Day 1 of each 3 week cycle (Q3W)
Dose Level 2: 30 μg/kg Day 1 Q3W
Dose Level 3: 60 μg/kg Day 1 Q3W
Dose Level 4: 90 μg/kg Day 1 Q3W
Dose Level 5: 120 μg/kg Day 1 Q3W
Dose Level 6: 150 μg/kg Day 1 Q3W
Dose Level 7: 200 μg/kg Day 1 Q3W and on Day 1 of each 6 week cycle (Q6W).
In Part 2 (expansion), participants received intravenous (IV) infusions of ADCT-402 at either 120 μg/kg or 150 μg/kg on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>PFS is defined among the efficacy population as the time from first dose of study drug until either disease progression or death due to any cause. Tumor response was assessed using the 2014 Lugano Classification for response.
Disease progression is defined as progressive metabolic disease or one of the follow:
Target node progression.
An individual extranodal lesion must be abnormal with length &gt;1.5cm and/or increase of length &gt;50%.
New or clear progression of nonmeasured lesions.
Regrowth of previously resolved lesions or new nodes &gt;1.5 cm in length.
New or recurrent bone marrow involvement.
PFS is presented overall for all participants who received ADCT-402, as specified in protocol section 7.4.</description>
          <population>All participants who received at least one dose of study treatment with a valid baseline disease assessment and at least one valid post-baseline disease assessment. Results are pooled for all arms as specified in the protocol.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" lower_limit="2.66" upper_limit="4.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Serum Concentration (Cmax) for ADCT-402</title>
        <description>Cmax for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
        <time_frame>Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)</time_frame>
        <population>Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 15 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 60 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 90 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O5">
            <title>Parts 1 and 2: 120 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.</description>
          </group>
          <group group_id="O6">
            <title>Parts 1 and 2: 150 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 200 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: 200 μg/kg Q6W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 6 week cycle (Q6W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Concentration (Cmax) for ADCT-402</title>
          <description>Cmax for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
          <population>Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="88"/>
                <count group_id="O7" value="14"/>
                <count group_id="O8" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PBD conjugated Ab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="88"/>
                    <count group_id="O7" value="14"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260" spread="85.5"/>
                    <measurement group_id="O2" value="404" spread="161"/>
                    <measurement group_id="O3" value="721" spread="481"/>
                    <measurement group_id="O4" value="1088" spread="748"/>
                    <measurement group_id="O5" value="2374" spread="1040"/>
                    <measurement group_id="O6" value="3416" spread="3093"/>
                    <measurement group_id="O7" value="3619" spread="688"/>
                    <measurement group_id="O8" value="3798" spread="1332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PBD conjugated Ab: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="72"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="398" spread="284"/>
                    <measurement group_id="O2" value="1971" spread="2566"/>
                    <measurement group_id="O3" value="864" spread="686"/>
                    <measurement group_id="O4" value="1416" spread="799"/>
                    <measurement group_id="O5" value="2573" spread="655"/>
                    <measurement group_id="O6" value="3776" spread="2738"/>
                    <measurement group_id="O7" value="4293" spread="1021"/>
                    <measurement group_id="O8" value="3178" spread="1733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total Ab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="88"/>
                    <count group_id="O7" value="14"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298" spread="83.7"/>
                    <measurement group_id="O2" value="542" spread="192"/>
                    <measurement group_id="O3" value="856" spread="475"/>
                    <measurement group_id="O4" value="1560" spread="1102"/>
                    <measurement group_id="O5" value="2829" spread="1257"/>
                    <measurement group_id="O6" value="4383" spread="4460"/>
                    <measurement group_id="O7" value="4185" spread="1308"/>
                    <measurement group_id="O8" value="4543" spread="1805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total Ab: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="72"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="447" spread="283"/>
                    <measurement group_id="O2" value="2906" spread="4034"/>
                    <measurement group_id="O3" value="1275" spread="1025"/>
                    <measurement group_id="O4" value="2422" spread="983"/>
                    <measurement group_id="O5" value="3142" spread="888"/>
                    <measurement group_id="O6" value="4798" spread="3334"/>
                    <measurement group_id="O7" value="5059" spread="1027"/>
                    <measurement group_id="O8" value="3834" spread="1913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SG3199: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="28"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="0.102" spread="NA">Standard deviation could not be determined as only one participant had evaluable data.</measurement>
                    <measurement group_id="O5" value="0.0372" spread="0.0208"/>
                    <measurement group_id="O6" value="0.0570" spread="0.0454"/>
                    <measurement group_id="O7" value="0.0479" spread="0.0381"/>
                    <measurement group_id="O8" value="0.0468" spread="0.0333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SG3199: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="0.0704" spread="0.0152"/>
                    <measurement group_id="O5" value="0.0403" spread="0.0116"/>
                    <measurement group_id="O6" value="0.0485" spread="0.0449"/>
                    <measurement group_id="O7" value="0.0293" spread="0.00329"/>
                    <measurement group_id="O8" value="0.0516" spread="0.0325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach the Maximum Serum Concentration (Tmax) for ADCT-402</title>
        <description>Tmax for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
        <time_frame>Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)</time_frame>
        <population>Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 15 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 60 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 90 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O5">
            <title>Parts 1 and 2: 120 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.</description>
          </group>
          <group group_id="O6">
            <title>Parts 1 and 2: 150 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 200 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: 200 μg/kg Q6W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 6 week cycle (Q6W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach the Maximum Serum Concentration (Tmax) for ADCT-402</title>
          <description>Tmax for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
          <population>Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="88"/>
                <count group_id="O7" value="14"/>
                <count group_id="O8" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PBD conjugated Ab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="88"/>
                    <count group_id="O7" value="14"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0837" lower_limit="0.0833" upper_limit="0.0854"/>
                    <measurement group_id="O2" value="0.0833" lower_limit="0.0431" upper_limit="0.319"/>
                    <measurement group_id="O3" value="0.0819" lower_limit="0.0417" upper_limit="0.0847"/>
                    <measurement group_id="O4" value="0.0500" lower_limit="0.0417" upper_limit="0.0875"/>
                    <measurement group_id="O5" value="0.0833" lower_limit="0.0403" upper_limit="0.296"/>
                    <measurement group_id="O6" value="0.0840" lower_limit="0.0417" upper_limit="0.305"/>
                    <measurement group_id="O7" value="0.0858" lower_limit="0.0417" upper_limit="0.285"/>
                    <measurement group_id="O8" value="0.0840" lower_limit="0.0417" upper_limit="0.276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PBD conjugated Ab: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="72"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.122" lower_limit="0.0660" upper_limit="0.170"/>
                    <measurement group_id="O2" value="0.0618" lower_limit="0.0417" upper_limit="0.0875"/>
                    <measurement group_id="O3" value="0.0417" lower_limit="0.0222" upper_limit="0.165"/>
                    <measurement group_id="O4" value="0.0833" lower_limit="0.0229" upper_limit="0.0882"/>
                    <measurement group_id="O5" value="0.0830" lower_limit="0.0208" upper_limit="0.278"/>
                    <measurement group_id="O6" value="0.0642" lower_limit="0.0208" upper_limit="1.00"/>
                    <measurement group_id="O7" value="0.0854" lower_limit="0.0208" upper_limit="1.00"/>
                    <measurement group_id="O8" value="0.0826" lower_limit="0.0257" upper_limit="0.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total Ab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="88"/>
                    <count group_id="O7" value="14"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0844" lower_limit="0.0438" upper_limit="0.292"/>
                    <measurement group_id="O2" value="0.0833" lower_limit="0.0431" upper_limit="0.0896"/>
                    <measurement group_id="O3" value="0.0833" lower_limit="0.0806" upper_limit="0.0847"/>
                    <measurement group_id="O4" value="0.0500" lower_limit="0.0417" upper_limit="0.169"/>
                    <measurement group_id="O5" value="0.0833" lower_limit="0.0403" upper_limit="0.294"/>
                    <measurement group_id="O6" value="0.0837" lower_limit="0.0403" upper_limit="0.299"/>
                    <measurement group_id="O7" value="0.0840" lower_limit="0.0417" upper_limit="0.285"/>
                    <measurement group_id="O8" value="0.0837" lower_limit="0.0417" upper_limit="0.271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total Ab: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="72"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0649" lower_limit="0.0431" upper_limit="0.0868"/>
                    <measurement group_id="O2" value="0.0618" lower_limit="0.0417" upper_limit="0.0875"/>
                    <measurement group_id="O3" value="0.0417" lower_limit="0.0222" upper_limit="0.0854"/>
                    <measurement group_id="O4" value="0.0833" lower_limit="0.0229" upper_limit="0.159"/>
                    <measurement group_id="O5" value="0.0632" lower_limit="0.0208" upper_limit="0.275"/>
                    <measurement group_id="O6" value="0.0639" lower_limit="0" upper_limit="2.11"/>
                    <measurement group_id="O7" value="0.132" lower_limit="0.0208" upper_limit="4.00"/>
                    <measurement group_id="O8" value="0.0858" lower_limit="0.0257" upper_limit="0.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SG3199: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="28"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="0.0833" lower_limit="0.0833" upper_limit="0.0833"/>
                    <measurement group_id="O5" value="0.0854" lower_limit="0.0458" upper_limit="0.172"/>
                    <measurement group_id="O6" value="0.0844" lower_limit="0.0417" upper_limit="0.294"/>
                    <measurement group_id="O7" value="0.128" lower_limit="0.0833" upper_limit="0.285"/>
                    <measurement group_id="O8" value="0.165" lower_limit="0.0417" upper_limit="6.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SG3199: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="1.05" lower_limit="0.0417" upper_limit="2.06"/>
                    <measurement group_id="O5" value="0.120" lower_limit="0.0840" upper_limit="0.153"/>
                    <measurement group_id="O6" value="0.0632" lower_limit="0.0222" upper_limit="13.8"/>
                    <measurement group_id="O7" value="0.165" lower_limit="0.0299" upper_limit="0.992"/>
                    <measurement group_id="O8" value="0.162" lower_limit="0.0833" upper_limit="0.280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Serum Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) for ADCT-402</title>
        <description>AUClast for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
        <time_frame>Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)</time_frame>
        <population>Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 15 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 60 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 90 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O5">
            <title>Parts 1 and 2: 120 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.</description>
          </group>
          <group group_id="O6">
            <title>Parts 1 and 2: 150 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 200 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: 200 μg/kg Q6W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 6 week cycle (Q6W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Serum Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) for ADCT-402</title>
          <description>AUClast for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
          <population>Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.</population>
          <units>day*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="88"/>
                <count group_id="O7" value="14"/>
                <count group_id="O8" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PBD conjugated Ab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="88"/>
                    <count group_id="O7" value="14"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1063" spread="1340"/>
                    <measurement group_id="O2" value="2390" spread="826"/>
                    <measurement group_id="O3" value="3875" spread="3228"/>
                    <measurement group_id="O4" value="6587" spread="6842"/>
                    <measurement group_id="O5" value="13544" spread="7503"/>
                    <measurement group_id="O6" value="14258" spread="8248"/>
                    <measurement group_id="O7" value="30571" spread="12425"/>
                    <measurement group_id="O8" value="30386" spread="16960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PBD conjugated Ab: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="72"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1933" spread="2289"/>
                    <measurement group_id="O2" value="2955" spread="1132"/>
                    <measurement group_id="O3" value="5573" spread="4827"/>
                    <measurement group_id="O4" value="10369" spread="11656"/>
                    <measurement group_id="O5" value="18707" spread="10505"/>
                    <measurement group_id="O6" value="23109" spread="15370"/>
                    <measurement group_id="O7" value="48183" spread="20288"/>
                    <measurement group_id="O8" value="39609" spread="24852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total Ab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="88"/>
                    <count group_id="O7" value="14"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1185" spread="1540"/>
                    <measurement group_id="O2" value="3194" spread="1136"/>
                    <measurement group_id="O3" value="5032" spread="4334"/>
                    <measurement group_id="O4" value="8869" spread="9108"/>
                    <measurement group_id="O5" value="15980" spread="7649"/>
                    <measurement group_id="O6" value="16973" spread="9745"/>
                    <measurement group_id="O7" value="33834" spread="14888"/>
                    <measurement group_id="O8" value="36099" spread="20829"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total Ab: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="72"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1924" spread="2576"/>
                    <measurement group_id="O2" value="3986" spread="1725"/>
                    <measurement group_id="O3" value="7958" spread="6882"/>
                    <measurement group_id="O4" value="14025" spread="15704"/>
                    <measurement group_id="O5" value="23428" spread="13513"/>
                    <measurement group_id="O6" value="28657" spread="19457"/>
                    <measurement group_id="O7" value="57450" spread="26899"/>
                    <measurement group_id="O8" value="49892" spread="31012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SG3199: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="28"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="0.00213" spread="NA">Standard deviation could not be determined as only one participant had evaluable data.</measurement>
                    <measurement group_id="O5" value="0.00462" spread="0.00671"/>
                    <measurement group_id="O6" value="0.0222" spread="0.0423"/>
                    <measurement group_id="O7" value="0.0174" spread="0.0303"/>
                    <measurement group_id="O8" value="0.0436" spread="0.0959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SG3199: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="0.0242" spread="0.0234"/>
                    <measurement group_id="O5" value="0.154" spread="0.286"/>
                    <measurement group_id="O6" value="0.0108" spread="0.0248"/>
                    <measurement group_id="O7" value="0.00425" spread="0.00461"/>
                    <measurement group_id="O8" value="0.00332" spread="0.00215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Serum Concentration-Time Curve From Time 0 to the End of the Dosing Interval (AUCtau) for ADCT-402</title>
        <description>AUCtau for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
        <time_frame>Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)</time_frame>
        <population>Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 15 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 60 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 90 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O5">
            <title>Parts 1 and 2: 120 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.</description>
          </group>
          <group group_id="O6">
            <title>Parts 1 and 2: 150 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 200 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: 200 μg/kg Q6W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 6 week cycle (Q6W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Serum Concentration-Time Curve From Time 0 to the End of the Dosing Interval (AUCtau) for ADCT-402</title>
          <description>AUCtau for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
          <population>Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.</population>
          <units>day*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="72"/>
                <count group_id="O7" value="11"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PBD conjugated Ab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>PBD conjugated Ab: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="72"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2285" spread="2928"/>
                    <measurement group_id="O2" value="3458" spread="1426"/>
                    <measurement group_id="O3" value="10575" spread="1121"/>
                    <measurement group_id="O4" value="10171" spread="11244"/>
                    <measurement group_id="O5" value="19890" spread="8968"/>
                    <measurement group_id="O6" value="22859" spread="12080"/>
                    <measurement group_id="O7" value="39362" spread="9800"/>
                    <measurement group_id="O8" value="38466" spread="23514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total Ab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>total Ab: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="72"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2636" spread="3387"/>
                    <measurement group_id="O2" value="4662" spread="2096"/>
                    <measurement group_id="O3" value="10211" spread="8827"/>
                    <measurement group_id="O4" value="17141" spread="15029"/>
                    <measurement group_id="O5" value="24247" spread="10902"/>
                    <measurement group_id="O6" value="28041" spread="15312"/>
                    <measurement group_id="O7" value="46469" spread="12675"/>
                    <measurement group_id="O8" value="48524" spread="28858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SG3199: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>SG3199: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf) for ADCT-402</title>
        <description>AUCinf for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
        <time_frame>Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)</time_frame>
        <population>Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 15 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 60 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 90 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O5">
            <title>Parts 1 and 2: 120 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.</description>
          </group>
          <group group_id="O6">
            <title>Parts 1 and 2: 150 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 200 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: 200 μg/kg Q6W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 6 week cycle (Q6W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf) for ADCT-402</title>
          <description>AUCinf for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
          <population>Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.</population>
          <units>day*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="47"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PBD conjugated Ab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="432" spread="173"/>
                    <measurement group_id="O2" value="2001" spread="663"/>
                    <measurement group_id="O3" value="5333" spread="4002"/>
                    <measurement group_id="O4" value="5622" spread="7170"/>
                    <measurement group_id="O5" value="10232" spread="6220"/>
                    <measurement group_id="O6" value="11498" spread="8175"/>
                    <measurement group_id="O7" value="29174" spread="25838"/>
                    <measurement group_id="O8" value="32629" spread="19488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PBD conjugated Ab: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>total Ab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="37"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="869" spread="NA">Standard deviation could not be determined as only one participant had evaluable data.</measurement>
                    <measurement group_id="O4" value="16409" spread="NA">Standard deviation could not be determined as only one participant had evaluable data.</measurement>
                    <measurement group_id="O5" value="13292" spread="8495"/>
                    <measurement group_id="O6" value="12692" spread="8968"/>
                    <measurement group_id="O7" value="38991" spread="53597"/>
                    <measurement group_id="O8" value="43952" spread="24032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total Ab: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>SG3199: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="0.154" spread="NA">Standard deviation could not be determined as only one participant had evaluable data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SG3199: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life (Thalf) of ADCT-402</title>
        <description>Thalf of Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
        <time_frame>Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)</time_frame>
        <population>Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 15 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 60 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 90 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O5">
            <title>Parts 1 and 2: 120 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.</description>
          </group>
          <group group_id="O6">
            <title>Parts 1 and 2: 150 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 200 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: 200 μg/kg Q6W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 6 week cycle (Q6W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (Thalf) of ADCT-402</title>
          <description>Thalf of Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
          <population>Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="69"/>
                <count group_id="O7" value="11"/>
                <count group_id="O8" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PBD conjugated Ab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" lower_limit="1.04" upper_limit="2.56"/>
                    <measurement group_id="O2" value="6.84" lower_limit="5.74" upper_limit="7.94"/>
                    <measurement group_id="O3" value="6.30" lower_limit="4.30" upper_limit="8.30"/>
                    <measurement group_id="O4" value="3.97" lower_limit="0.923" upper_limit="7.01"/>
                    <measurement group_id="O5" value="6.33" lower_limit="0.515" upper_limit="9.50"/>
                    <measurement group_id="O6" value="6.43" lower_limit="0.146" upper_limit="13.1"/>
                    <measurement group_id="O7" value="7.96" lower_limit="6.43" upper_limit="16.6"/>
                    <measurement group_id="O8" value="10.4" lower_limit="0.0560" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PBD conjugated Ab: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="38"/>
                    <count group_id="O6" value="69"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.98" lower_limit="0.909" upper_limit="11.1"/>
                    <measurement group_id="O2" value="10.1" lower_limit="6.72" upper_limit="17.1"/>
                    <measurement group_id="O3" value="16.3" lower_limit="11.1" upper_limit="21.4"/>
                    <measurement group_id="O4" value="11.4" lower_limit="1.78" upper_limit="19.2"/>
                    <measurement group_id="O5" value="12.5" lower_limit="1.74" upper_limit="28.7"/>
                    <measurement group_id="O6" value="11.6" lower_limit="1.50" upper_limit="33.0"/>
                    <measurement group_id="O7" value="16.3" lower_limit="8.14" upper_limit="28.8"/>
                    <measurement group_id="O8" value="15.5" lower_limit="4.82" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total Ab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="37"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" lower_limit="2.75" upper_limit="2.75"/>
                    <measurement group_id="O4" value="8.82" lower_limit="8.82" upper_limit="8.82"/>
                    <measurement group_id="O5" value="7.00" lower_limit="0.325" upper_limit="10.6"/>
                    <measurement group_id="O6" value="6.58" lower_limit="0.0759" upper_limit="17.7"/>
                    <measurement group_id="O7" value="9.39" lower_limit="0.661" upper_limit="18.1"/>
                    <measurement group_id="O8" value="12.7" lower_limit="0.248" upper_limit="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total Ab: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="66"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.71" lower_limit="0.860" upper_limit="13.0"/>
                    <measurement group_id="O2" value="9.58" lower_limit="7.11" upper_limit="15.4"/>
                    <measurement group_id="O3" value="16.5" lower_limit="12.9" upper_limit="20.0"/>
                    <measurement group_id="O4" value="13.4" lower_limit="1.27" upper_limit="38.5"/>
                    <measurement group_id="O5" value="14.9" lower_limit="2.07" upper_limit="33.5"/>
                    <measurement group_id="O6" value="14.3" lower_limit="0.269" upper_limit="36.0"/>
                    <measurement group_id="O7" value="14.7" lower_limit="8.47" upper_limit="27.8"/>
                    <measurement group_id="O8" value="18.4" lower_limit="6.18" upper_limit="39.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SG3199: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>SG3199: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance (CL) at Steady State for ADCT-402</title>
        <description>CL of Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
        <time_frame>Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)</time_frame>
        <population>Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 15 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 60 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 90 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O5">
            <title>Parts 1 and 2: 120 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.</description>
          </group>
          <group group_id="O6">
            <title>Parts 1 and 2: 150 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 200 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: 200 μg/kg Q6W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 6 week cycle (Q6W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance (CL) at Steady State for ADCT-402</title>
          <description>CL of Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
          <population>Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.</population>
          <units>liters/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="72"/>
                <count group_id="O7" value="11"/>
                <count group_id="O8" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PBD conjugated Ab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.49" spread="0.978"/>
                    <measurement group_id="O2" value="1.08" spread="0.164"/>
                    <measurement group_id="O3" value="0.696" spread="0.444"/>
                    <measurement group_id="O4" value="7.13" spread="8.91"/>
                    <measurement group_id="O5" value="2.09" spread="4.07"/>
                    <measurement group_id="O6" value="3.84" spread="8.53"/>
                    <measurement group_id="O7" value="3.11" spread="5.30"/>
                    <measurement group_id="O8" value="12.6" spread="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PBD conjugated Ab: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="72"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" spread="1.80"/>
                    <measurement group_id="O2" value="0.646" spread="0.348"/>
                    <measurement group_id="O3" value="0.415" spread="0.205"/>
                    <measurement group_id="O4" value="19.6" spread="40.6"/>
                    <measurement group_id="O5" value="17.8" spread="109"/>
                    <measurement group_id="O6" value="0.986" spread="2.48"/>
                    <measurement group_id="O7" value="0.407" spread="0.143"/>
                    <measurement group_id="O8" value="0.349" spread="0.210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total Ab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="37"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="NA">Standard deviation could not be determined as only one participant had evaluable data.</measurement>
                    <measurement group_id="O4" value="0.640" spread="NA">Standard deviation could not be determined as only one participant had evaluable data.</measurement>
                    <measurement group_id="O5" value="2.47" spread="5.00"/>
                    <measurement group_id="O6" value="3.87" spread="8.95"/>
                    <measurement group_id="O7" value="7.12" spread="9.62"/>
                    <measurement group_id="O8" value="2.02" spread="5.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total Ab: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="72"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="1.71"/>
                    <measurement group_id="O2" value="0.577" spread="0.309"/>
                    <measurement group_id="O3" value="38.1" spread="65.5"/>
                    <measurement group_id="O4" value="1.42" spread="2.06"/>
                    <measurement group_id="O5" value="0.581" spread="0.660"/>
                    <measurement group_id="O6" value="1.05" spread="2.91"/>
                    <measurement group_id="O7" value="0.417" spread="0.161"/>
                    <measurement group_id="O8" value="0.323" spread="0.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SG3199: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="627" spread="NA">Standard deviation could not be determined as only one participant had evaluable data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SG3199: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution at Steady State (Vss) for ADCT-402</title>
        <description>Vss for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
        <time_frame>Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)</time_frame>
        <population>Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 15 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 60 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 90 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O5">
            <title>Parts 1 and 2: 120 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.</description>
          </group>
          <group group_id="O6">
            <title>Parts 1 and 2: 150 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 200 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: 200 μg/kg Q6W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 6 week cycle (Q6W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady State (Vss) for ADCT-402</title>
          <description>Vss for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
          <population>Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="69"/>
                <count group_id="O7" value="11"/>
                <count group_id="O8" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PBD conjugated Ab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.47" spread="0.759"/>
                    <measurement group_id="O2" value="10.3" spread="4.83"/>
                    <measurement group_id="O3" value="4.96" spread="0.318"/>
                    <measurement group_id="O4" value="9.68" spread="2.68"/>
                    <measurement group_id="O5" value="5.95" spread="1.86"/>
                    <measurement group_id="O6" value="7.59" spread="6.18"/>
                    <measurement group_id="O7" value="11.5" spread="11.1"/>
                    <measurement group_id="O8" value="7.18" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PBD conjugated Ab: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="38"/>
                    <count group_id="O6" value="69"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.82" spread="1.25"/>
                    <measurement group_id="O2" value="10.1" spread="8.57"/>
                    <measurement group_id="O3" value="8.29" spread="0.540"/>
                    <measurement group_id="O4" value="7.62" spread="1.09"/>
                    <measurement group_id="O5" value="6.71" spread="3.13"/>
                    <measurement group_id="O6" value="7.48" spread="4.29"/>
                    <measurement group_id="O7" value="9.18" spread="3.43"/>
                    <measurement group_id="O8" value="6.21" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total Ab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="37"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.71" spread="NA">Standard deviation could not be determined as only one participant had evaluable data.</measurement>
                    <measurement group_id="O4" value="7.84" spread="NA">Standard deviation could not be determined as only one participant had evaluable data.</measurement>
                    <measurement group_id="O5" value="5.51" spread="1.29"/>
                    <measurement group_id="O6" value="6.60" spread="3.16"/>
                    <measurement group_id="O7" value="7.91" spread="0.0252"/>
                    <measurement group_id="O8" value="7.20" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total Ab: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="66"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.83" spread="0.854"/>
                    <measurement group_id="O2" value="9.62" spread="8.54"/>
                    <measurement group_id="O3" value="7.30" spread="1.38"/>
                    <measurement group_id="O4" value="8.52" spread="1.34"/>
                    <measurement group_id="O5" value="8.11" spread="4.57"/>
                    <measurement group_id="O6" value="8.21" spread="3.64"/>
                    <measurement group_id="O7" value="9.46" spread="5.26"/>
                    <measurement group_id="O8" value="6.86" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SG3199: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="335" spread="NA">Standard deviation could not be determined as only one participant had evaluable data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SG3199: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation Index (AI) for ADCT-402</title>
        <description>AI for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199). AI is the ratio of area under the serum concentration-time curve (AUC) from 0 to 21 days for Cycle 2 divided by AUC from 0 to 21 days for Cycle 1 (Q3W schedule: 3 week cycle length; Q6W schedule: 6 week cycle length). It is the increase in drug plasma concentration after multiple dosing until a steady state is reached.
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
        <time_frame>Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)</time_frame>
        <population>Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 15 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 60 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 90 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
          <group group_id="O5">
            <title>Parts 1 and 2: 120 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.</description>
          </group>
          <group group_id="O6">
            <title>Parts 1 and 2: 150 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 200 μg/kg Q3W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: 200 μg/kg Q6W</title>
            <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 6 week cycle (Q6W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Index (AI) for ADCT-402</title>
          <description>AI for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199). AI is the ratio of area under the serum concentration-time curve (AUC) from 0 to 21 days for Cycle 2 divided by AUC from 0 to 21 days for Cycle 1 (Q3W schedule: 3 week cycle length; Q6W schedule: 6 week cycle length). It is the increase in drug plasma concentration after multiple dosing until a steady state is reached.
Results for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.</description>
          <population>Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="69"/>
                <count group_id="O7" value="11"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PBD conjugated Ab: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="38"/>
                    <count group_id="O6" value="69"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="0.173"/>
                    <measurement group_id="O2" value="1.37" spread="0.264"/>
                    <measurement group_id="O3" value="1.70" spread="0.467"/>
                    <measurement group_id="O4" value="1.42" spread="0.399"/>
                    <measurement group_id="O5" value="1.47" spread="0.369"/>
                    <measurement group_id="O6" value="1.46" spread="0.368"/>
                    <measurement group_id="O7" value="1.76" spread="0.385"/>
                    <measurement group_id="O8" value="1.23" spread="0.160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total Ab: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="66"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.229"/>
                    <measurement group_id="O2" value="1.35" spread="0.252"/>
                    <measurement group_id="O3" value="1.71" spread="0.325"/>
                    <measurement group_id="O4" value="1.80" spread="0.962"/>
                    <measurement group_id="O5" value="1.62" spread="0.492"/>
                    <measurement group_id="O6" value="1.63" spread="0.486"/>
                    <measurement group_id="O7" value="1.78" spread="0.418"/>
                    <measurement group_id="O8" value="1.36" spread="0.314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SG3199: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anti-drug Antibody Response (ADA) Against ADCT-402</title>
        <description>Blood serum samples were collected and analysed to determine the presence or absence of ADA.
ADA is presented overall for all participants who received ADCT-402, as specified in protocol section 7.4.</description>
        <time_frame>Q3W schedule: Day 1 to End of Cycle 1 (3 weeks); Q6W schedule: Day 1 to End of Cycle 1 (6 weeks)</time_frame>
        <population>All participants who were tested for ADA.</population>
        <group_list>
          <group group_id="O1">
            <title>Parts 1 and 2: ADCT-402</title>
            <description>In Part 1 (dose escalation) participants received intravenous (IV) infusions of ADCT-402, at escalating doses according to a 3+3 study design. Doses assessed:
Dose Level 1: 15 μg/kg on Day 1 of each 3 week cycle (Q3W)
Dose Level 2: 30 μg/kg Day 1 Q3W
Dose Level 3: 60 μg/kg Day 1 Q3W
Dose Level 4: 90 μg/kg Day 1 Q3W
Dose Level 5: 120 μg/kg Day 1 Q3W
Dose Level 6: 150 μg/kg Day 1 Q3W
Dose Level 7: 200 μg/kg Day 1 Q3W and on Day 1 of each 6 week cycle (Q6W).
In Part 2 (expansion), participants received intravenous (IV) infusions of ADCT-402 at either 120 μg/kg or 150 μg/kg on Day 1 of each 3 week cycle (Q3W).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-drug Antibody Response (ADA) Against ADCT-402</title>
          <description>Blood serum samples were collected and analysed to determine the presence or absence of ADA.
ADA is presented overall for all participants who received ADCT-402, as specified in protocol section 7.4.</description>
          <population>All participants who were tested for ADA.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Confirmed positive ADA pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed positive ADA post-dose only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed positive ADA at anytime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 to End of Study (a maximum of 18 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part 1: 15 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="E2">
          <title>Part 1: 30 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="E3">
          <title>Part 1: 60 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="E4">
          <title>Part 1: 90 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="E5">
          <title>Part 1: 120 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="E6">
          <title>Part 2: 120 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="E7">
          <title>Part 1: 150 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="E8">
          <title>Part 2: 150 μg/kg Q3W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W).</description>
        </group>
        <group group_id="E9">
          <title>Part 1: 200 μg/kg Q3W and Q6W</title>
          <description>Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Following protocol amendment 5, treatment cycle length was increased to 6 weeks (Q6W).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="47" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="20" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="40" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="15" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Abdominal compartment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Injection site extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Oropharyngeal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pneumonia haemophilus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Progressive multifocal leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Neck mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Burkitt's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema genital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Perineal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Scrotal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="19" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="65" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="36" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="25" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="22" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="16" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Anal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="24" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="16" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="22" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Corona virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="17" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="16" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Limb mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dermatitis bullous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI can publish after first multi-site publication, or if no multi-site publication is made within 18 months of study completion/termination. The only disclosure restriction on the PI is the sponsor can review results comms. prior to public release and can embargo comms. regarding trial results for a period that is more than 60 but less than or equal to 180 days from the time submitted to sponsor for review. The sponsor can’t require changes to the communication and can’t extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>ADC Therapeutics</name_or_title>
      <organization>ADC Therapeutics</organization>
      <phone>954-903-7994</phone>
      <email>clinical.trials@adctherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

